NASDAQ:NEPH Nephros (NEPH) Stock Price, News & Analysis $2.92 +0.29 (+11.03%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.82 -0.11 (-3.60%) As of 05/23/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nephros Stock (NASDAQ:NEPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nephros alerts:Sign Up Key Stats Today's Range$2.62▼$2.9650-Day Range$1.49▼$2.9252-Week Range$1.36▼$2.96Volume75,079 shsAverage Volume12,307 shsMarket Capitalization$30.95 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewNephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Read More… Nephros Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreNEPH MarketRank™: Nephros scored higher than 38% of companies evaluated by MarketBeat, and ranked 644th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNephros has received no research coverage in the past 90 days.Read more about Nephros' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Nephros is -32.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nephros is -32.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNephros has a P/B Ratio of 3.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nephros' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.09% of the float of Nephros has been sold short.Short Interest Ratio / Days to CoverNephros has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nephros has recently decreased by 28.95%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNephros does not currently pay a dividend.Dividend GrowthNephros does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.09% of the float of Nephros has been sold short.Short Interest Ratio / Days to CoverNephros has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nephros has recently decreased by 28.95%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Nephros to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nephros insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Nephros is held by insiders.Percentage Held by Institutions41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nephros' insider trading history. Receive NEPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter. Email Address NEPH Stock News HeadlinesNephros First Quarter 2025 Earnings: Beats ExpectationsMay 10, 2025 | finance.yahoo.comNephros Schedules First Quarter 2025 Financial Results Conference CallApril 30, 2025 | finance.yahoo.comMemorial Day Sale! 82% Off Disruptors and Dominators!Robots aren't coming to America in 2025. They are already here. In fact, I believe these robots could impact 65 million Americans lives — by August of this year.May 24, 2025 | Weiss Ratings (Ad)Nephros expands filtration line with new S100 In-Line filterApril 30, 2025 | investing.comNephros Launches New S100 In-Line MicrofilterApril 28, 2025 | finance.yahoo.comNephros Full Year 2024 Earnings: Beats ExpectationsMarch 28, 2025 | finance.yahoo.comEQS-News: Nephros Announces Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 8, 2025 | markets.businessinsider.comNephros Announces Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 7, 2025 | theglobeandmail.comSee More Headlines NEPH Stock Analysis - Frequently Asked Questions How have NEPH shares performed this year? Nephros' stock was trading at $1.47 on January 1st, 2025. Since then, NEPH stock has increased by 98.6% and is now trading at $2.92. View the best growth stocks for 2025 here. How were Nephros' earnings last quarter? Nephros, Inc. (NASDAQ:NEPH) released its earnings results on Thursday, May, 15th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.06. The company had revenue of $4.88 million for the quarter, compared to analyst estimates of $3.67 million. Nephros had a negative net margin of 6.86% and a negative trailing twelve-month return on equity of 11.39%. Who are Nephros' major shareholders? Nephros' top institutional shareholders include Bard Associates Inc. (1.35%). Insiders that own company stock include Arthur H Amron and Robert R Jr Banks. View institutional ownership trends. How do I buy shares of Nephros? Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nephros own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nephros investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Jabil (JBL), Arista Networks (ANET), Disc Medicine (IRON) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings5/15/2025Today5/24/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:NEPH CIK1196298 Webwww.nephros.com Phone(201) 343-5202Fax201-343-5207Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+71.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.07 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,580,000.00 Net Margins-6.86% Pretax Margin-6.86% Return on Equity-11.39% Return on Assets-8.30% Debt Debt-to-Equity RatioN/A Current Ratio6.95 Quick Ratio4.02 Sales & Book Value Annual Sales$15.52 million Price / Sales1.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book3.65Miscellaneous Outstanding Shares10,600,000Free Float10,112,000Market Cap$30.95 million OptionableNot Optionable Beta0.81 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:NEPH) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersMarket chaos is the new normalIt happened again. Wall Street swung like a wrecking ball after Trump paused tariffs on smartphones, lapto...Augusta Precious Metals | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.